摘要
目的探讨化疗联合重组人血管内皮抑制素治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法将54例NSCLC患者随机分为观察组(28例)和对照组(26例),观察组患者采用长春瑞滨和奥沙利铂联合恩度方案治疗,对照组患者采用多烯紫杉醇和奥沙利铂联合恩度方案治疗,比较两组患者的治疗效果和不良反应。结果 54例患者均完成2个周期化疗后进行疗效评定,观察组无完全缓解(CR)患者,部分缓解(PR)13例,病情稳定(SD)11例,疾病进展(PD)4例,有效率(RR)为46.4%。对照组患者无完全缓解,(PR)5例,(SD)10例,(PD)11例,有效率为19.2%。两组有效率比较,差异有统计学意义(P<0.05)。两组患者的主要不良反应为白细胞减少、血小板减少和恶心呕吐。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论长春瑞滨和奥沙利铂联合恩度治疗晚期NSCLC近期疗效显著,是一种安全、有效的治疗方案,值得临床进一步推广。
Objective To investigate the clinical curative effect of chemotherapy combined with re- combinant human endostatin therapy in the treatment of advanced non small cell lung cancer （NSCLC）. Methods 54 patients with NSCLC were divided into observation group（28 cases） and control group（26 ca- ses） by random number table. The observation group used changchun vinorelbine and oxaliplatin plus en- dostar therapy, the control group using doeetaxel and oxaliplatin plus endostar therapy. The curative effect and the side effects of chemotherapy were compered beteen the two groups. Results All of the 54 patients completed two cycles of chemotherapy after curative effect evaluation, the observation group without com- plete remission, partial remission in 13 cases, stable disease in 11 cases, 4 cases of disease progression, the effective rate of treatment was 46. 4%. The control group had no complete remission, partial remission in 5 patients, 10 patients with stable disease, the progression of the disease in I 1 cases, the effective rate of treatment was 19. 2%. the difference was statistically significant between the two groups （P 〈0. 05 ）. The main adverse reactions of the two groups of patients was leukopenia, thrombocytopenia, nausea and vomi- ting, there was no significant difference between the two groups （P 〉 0.05 ）. Conclusions The curative effect of vinorelbine and oxaliplatin plus endostar therapy in the treatment of advanced NSCLC was good, it was safe, effective treatment and worthy of further promotion.
出处
《中国肿瘤临床与康复》
2013年第4期341-343,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
